Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug under Real-World watch for tough stomach cancer

NCT ID NCT05993234

Disease control Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including time to next treatment and safety events. The goal is to see if T-DXd helps control the disease in a real-world setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 257 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with advanced HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen in a real-world setting in Europe.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GEJ adenocarcinoma who have received a prior trastuzumab based regimen * Histological or cytological confirmed diagnosis of advanced HER2 positive gastric cancer or GEJ * Documented HER2 + status (archival sample or recent sample prior 2L therapy) * Decision to newly initiate monotherapy T-DXd or conventional therapies per SMPC according to the physician's choice * Written dated and signed Informed Consent (ICF) to participate in the study Exclusion Criteria: * Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded * Pregnancy or breastfeeding No specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-positive advanced gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-positive advanced gastric cancer HER2-positive gastroesophageal junction adenocarcinoma

Contacts and locations

Locations

  • AO "Cardinale Giovanni Panico"

    Tricase, 73039, Italy

  • AOU Careggi

    Florence, 50134, Italy

  • AOU Pisana - Stabilimento Santa Chiara

    Pisa, 56126, Italy

  • ARNAS Garibaldi - PO Nesima

    Catania, 95122, Italy

  • AUSL della Romagna - Ospedale "S. Maria delle Croci" di Ravenna

    Ravenna, 48121, Italy

  • Alb Fils Kliniken GmbH

    Göppingen, 73035, Germany

  • Antwerp University Hospital

    Edegem, 2650, Belgium

  • Azienda Ospedaliero-Universitaria di Modena

    Modena, 41124, Italy

  • CHU Helora Hospital de La Louvière - Site Jolimont

    Haine-Saint-Paul, 7100, Belgium

  • CaritasKlinikum Saarbrücken

    Saarbrücken, 66113, Germany

  • Charite Campus Benjamin Franklin

    Berlin, 12203, Germany

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Gemeinschaftspraxis Dr. Haytham Kamal / Dr. David C. Dorn

    Hanover, 30625, Germany

  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE)

    Hamburg, 20249, Germany

  • IRCCS "S. De Bellis"

    Castellana Grotte, 70013, Italy

  • IRCCS AOU San Martino

    Genova, 16132, Italy

  • IRCCS Ospedale San Raffaele

    Milan, 20132, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, 80131, Italy

  • JESSA Hasselt

    Hasselt, 3500, Belgium

  • KRH Klinikum Siloah

    Hanover, 30459, Germany

  • Kepler Universitätsklinikum

    Wels, 4600, Austria

  • Klinikum am Steinenberg Reutlingen

    Reutlingen, 72764, Germany

  • Klinikum rechts der Isar der Technischen Universität München

    München, 81675, Germany

  • Krankenhaus St. Vinzenz in Zams

    Zams, 6511, Austria

  • Landesklinikum Wiener Neustadt

    Wiener Neustadt, 2700, Austria

  • MV-Zentrum für Hämatologie & Onkologie

    Cologne, 50677, Germany

  • MVZ am Klinikum Aschaffenburg

    Aschaffenburg, 63739, Germany

  • Medizinische Universität Wien

    Vienna, 1090, Austria

  • OLV Hospital Aalst

    Aalst, 9300, Belgium

  • Ordensklinikum Linz GmbH Barmherzige Schwestern

    Linz, 4010, Austria

  • Policlinico Universitario Campus Bio-Medico

    Roma, 00128, Italy

  • Praxis Onkologie Rheinsieg

    Troisdorf, 53840, Germany

  • Studienzentrum am Raschplatz GbR

    Hanover, 30161, Germany

  • UZ Brussel

    Jette, 3000, Belgium

  • UZ Gent

    Ghent, 9000, Belgium

  • University Hospital Essen

    Essen, 45147, Germany

  • Università degli studi di Napoli Federico II

    Naples, 80131, Italy

  • Università della Campania 'Luigi Vanvitelli'

    Naples, 80131, Italy

  • Vivantes Klinikum im Friedrichshain

    Berlin, 10249, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.